Predict the therapeutic response of antiviral therapy in Hepatitis C Virus (HCV) infected patients.

The IL28B RealFast™ Assay helps to predict the success of antiviral therapy and sustained virologic response (SVR) in Hepatitis C Virus (HCV) infected patients.

 

IL28B

 

  • Direct-acting antivirals and pegylated Interferon/Ribavirin regimens are used for the treatment of HCV infection.
  • SVR is dependent on virus genotype and on patients’ factors like age, sex, ethnicity and genetic variants associated with antiviral activity.
  • The functional variant rs368234815 TT>ΔG regulating IL28B expression is the strongest known host factor for predicting HCV clearance.
  • Genotyping of rs368234815 TT>ΔG helps to predict spontaneous and treatment-induced viral clearance in patients independent of their ethnicity.

 

ProductREFUnit SizeIFUBrochure
IL28B RealFast™ Assay7-200
7-203
100 rxn
32 rxn

PDF

PDF